Maridebart cafraglutide
Also known as MariTide, AMG 133
One-dose burn-down
Half-life
3.0 weeks
Tmax
7.0 days
Steady state
~90d
Typical dose
140 mg
Investigational peptide–antibody conjugate (GLP-1 receptor agonist + GIP receptor antagonist) for obesity, designed for monthly or less-frequent dosing.
Mechanism of action
Two GLP-1 analog peptides conjugated to an anti-GIPR antibody give a very long half-life; combines GLP-1 agonism with GIP-receptor antagonism.
Investigational — not approved. Half-life ~21 days supports monthly dosing; trial doses vary widely, so the default here is illustrative.
Track Maridebart cafraglutide for free
Log your doses and PeptideBuddy models Maridebart cafraglutide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free